Navigation Links
Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Date:11/1/2007

DURHAM, N.C., Nov. 1 /PRNewswire/ -- Regado Biosciences today announced the enrollment of the first patient in a multi-center, open-label, randomized Phase IIa clinical study, named REVERSAL-PCI, of its REG1 Anticoagulation System. The patient was enrolled at Black Hills Cardiology in Rapid City, SD. The study will enroll 26 patients undergoing elective Percutaneous Coronary Intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon angioplasty dilatation and stenting on patients at low-risk for complications associated with therapy-related bleeding or heart attack. The REG1 Anticoagulation System is a combination of RB006, an intravenous anticoagulant, and its highly specific, rapidly acting antidote, RB007.

All patients will be pretreated with clopidogrel and aspirin to inhibit platelet activity. Primary procedural success will be defined by absence of significant bleeding events up to hospital discharge or 48 hours post stenting, and by absence of death, nonfatal heart attack, or need to repeat revascularization up to day 14. The study will be conducted at sites in the United States and Argentina.

"There is a significant and immediate need for an anticoagulant therapy that can be adjusted quickly and easily based on the changing medical condition of the patient. Our Phase I studies in healthy volunteers and in patients with stable coronary artery disease showed REG1 provided a safe, potent, and quickly reversible anticoagulant effect," stated Douglas Gooding, Chief Executive Officer of Regado Biosciences. "Our plan is to build on our existing data set and initiate several additional Phase II studies to establish proof of concept in a wide range of coronary revascularization procedures."

Regado has conducted three Phase I clinical studies of REG1, all of which demonstrated the anticoagulation system is safe and the antidote effective in both healthy volunteers and in older pati
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Investor-Edge has initiated coverage on the following equities: ... Company (NYSE: LLY ), Nektar Therapeutics (NASDAQ: ... Novartis AG (NYSE: NVS ). Free research on ... . On Friday, December 12, 2014, the NASDAQ Composite ... lost 1.79%, to finish the day at 17,280.83, and the ...
(Date:12/15/2014)... , Dec. 15, 2014  Stephen Squires, CEO and ... Quantum Materials Corp (OTCQB:QTMM), will be speaking at ... Materials (RCQM) on December 16th, 2014. The RCQM launch ... nanomaterials in attracting top faculty and students and by ... on research. "We have a long ...
(Date:12/15/2014)...  The Government of Ghana has endorsed ... (GBF) and Terumo BCT to respond to the emerging Ebola crisis ... long-term health system capacity to the citizens of Ghana ... Ebola Readiness and Resilience Initiative (GERRI) is a multi-agency effort designed ... the possible arrival of the Ebola epidemic , Provide new ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6
... , , , ... The rating agency Moody,s changed the outlook for ... , Moody,s gave as a ... the group,s business model. , , , ...
... INDIANAPOLIS , April 22 Today, WellPoint, Inc. (NYSE: ... article published this morning. , , ... Today,s Reuters story alleging that WellPoint employs a ... inaccurate and grossly misleading . The story incorrectly reports that WellPoint singles out ...
Cached Medicine Technology:Moody's Raised Outlook for Gerresheimer 2WellPoint's Reuters Response 2WellPoint's Reuters Response 3WellPoint's Reuters Response 4
(Date:12/17/2014)... By Kathleen Doheny ... -- Chronic sleep loss is rampant in America, and work ... "Work is the No. 1 sleep killer," said Dr. Mathias ... at the University of Pennsylvania Perelman School of Medicine. ... and older, found that work is the main activity exchanged ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Main Street ... clinic, is weighing in on a new study providing ... on the oral hygiene of children. , Sufficient enough ... drinks, such as pop or juice drinks, with the ... looming, however, is whether drinks listed as 100% fruit ...
(Date:12/15/2014)... Health Dialog, a leading provider ... it has received Patient Oriented Accreditation from the ... Disease Management (DM) Programs for asthma, congestive heart ... disease and diabetes. This marks the 12th continuous ... Disease Management (DM) Programs, reaffirming Health Dialog’s focus ...
(Date:12/15/2014)... Kathy McAfee, America's Marketing Motivator, was announced ... the category of Best Blog 2014. McAfee received the ... career blog Networking Ahead which combines many ... their talent and influence through better networking, leadership and ... Networking Ahead for Business, has been motivating readers for ...
(Date:12/15/2014)... 15, 2014 Bacteroides is becoming the indicator ... it much more prevalent than coliforms, it cannot reproduce in ... environment. , Key Benefits of the new Bacteroides Sewage ... , Eliminates false positives from coliforms naturally occurring ... , Maintain the same sampling method with ...
Breaking Medicine News(10 mins):Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... N.J., Nov. 6 Osteotech, Inc.,(Nasdaq: OSTE ) ... to $25.7 million from third quarter 2006 revenue of ... 28% to $17.6 million for the three months ended ... from the same segments for the,third quarter of 2006. ...
... Thursday, November 8,2007, at 8:30 a.m. Eastern/2:30 p.m. Central ... CTIC and MTAX: CTIC),management team will host ... quarter achievements and financial results. Conference Call ... a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time ...
... SOUTH SAN FRANCISCO, Calif., Nov. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... and nine months ended September 30, 2007. For the ... $18.9,million, or $0.61 per share, compared to a net loss ... of 2006. Weighted average shares,outstanding for the third quarters of ...
... 6 - Elsevier Signs Agreement With ... major global healthcare company, Bayer,HealthCare AG, headquartered in ... Classic. Available in electronic format for,the first time, ... from 43 Excerpta Medica Abstract Journals published between ...
... TSX: COM, VANCOUVER, Nov. 5 /PRNewswire-FirstCall/ - Cardiome ... Bob Rieder, Chairman and,Chief Executive Officer, will present an ... Conference in New York at 1:20pm Eastern,Time (10:20am Pacific ... webcast of Mr. Rieder,s presentation can be accessed on,Cardiome,s ...
... StatSure Diagnostic,Systems, Inc. (OTC Bulletin Board: SSUR.OB) ... ("FDA"), through its Center for Devices and,Radiological Health, ... Amendments of 1988 ("CLIA") for an HIV 1/2 ... HIV 1/2 product,is marketed and distributed worldwide by ...
Cached Medicine News:Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 2Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 3Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 4Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 5Health News:Rigel Announces Third Quarter 2007 Financial Results 2Health News:Rigel Announces Third Quarter 2007 Financial Results 3Health News:Rigel Announces Third Quarter 2007 Financial Results 4Health News:EMBASE Classic Makes Inroads into Pharmaceutical Industry 2Health News:EMBASE Classic Makes Inroads into Pharmaceutical Industry 3Health News:Cardiome to Present at CIBC Conference 2Health News:Cardiome to Present at CIBC Conference 3Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 3
Curved shafts and tips with tying surfaces. Wide serrated handle with dull finish. Overall length 4.3 inches....
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
Straight shafts with 5 mm tying platform. Wide handle with dull finish. Overall length 4.3 inches....
Straight shafts with 7 mm tying platform. Flat serrated handle with dull titanium finish. Overall length 4.5 inches....
Medicine Products: